A Pharmacodynamic Study With Ticagrelor in Hispanic Patients

• Inhibition of the P2Y12 receptor measured by Platelet Reactivity Unit [ Time Frame: At 0.5 and 8 hours after the loading dose ] [ Designated as safety issue: No ]
• Inhibition of the P2Y12 receptor measured by Platelet Reactivity Unit [ Time Frame: At 2, 8 and 24 hours from last dose ] [ Designated as safety issue: No ]
• Area under the plasma concentration versus time curve (AUC) of ticagrelor [ Time Frame: Predose, 0.5, 2, 8 from loading dose; 0, 2, 8 and 24 from last dose ] [ Designated as safety issue: No ]

The purpose of this study is to assess the pharmacodynamic effect of ticagrelor in Hispanic patients with stable coronary artery disease.

A Randomized, Open-Label, Multiple Dose, Crossover, Multiple Center Study of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Hispanic Patients with Stable Coronary Artery Disease

• Drug: Ticagrelor
  Min - 90mg/Max - 180mg tablets (loading dose)
• Drug: Clopidogrel
  75mg (once daily)/Max - 600mg tablets (loading dose)

• Experimental: Ticagrelor
  Intervention: Drug: Ticagrelor
• Active Comparator: Clopidogrel
  Intervention: Drug: Clopidogrel

Inclusion Criteria:

• Provision of signed and dated informed consent before initiation of any study-related procedures
• Male or female patients aged 18 years or older Documented stable CAD fulfilling and taking 75-100mg ASA daily treatment
• Females must be post menopausal or surgically sterile Self-identified as Hispanic

Exclusion Criteria:

• Any indication for oral anticoagulant (e.g., atrial fibrillation, mitral stenosis or prosthetic heart valve) or dual antiplatelet treatment (e.g., clopidogrel, prasugrel, ASA dose other than 75 to 100 mg daily) during study period
• Patients who had ACS or stent placed within 12 months of screening Patients with a history of moderate or severe hepatic impairment
• Current smokers, including the use of tobacco containing products in the past 1 month of randomization
• Patients requiring dialysis